US FDA Has 10 Months To Provide Answer On Perrigo/HRA OTC Oral Contraceptive Application
Executive Summary
Perrigo's HRA Pharma submits to FDA on 11 July an NDA by for OTC 0.075-mg norgestrel, branded Opill, The same formulation previously was available Rx 30 years.
You may also be interested in...
FDA Moves On NDA For First US OTC Birth Control, Scheduling Joint Ad Comm Meeting
The US FDA has scheduled a joint advisory committee meeting for November to review Perrigo subsidiary HRA Pharma’s new drug application for Rx-to-OTC switch of Opill (0.075-mg norgestrel), which would represent the first birth control pill available in the US without a prescription.
Perrigo Delivers ‘Remarkable Quarter’ As OTC Birth Control Waits In Wings
Perrigo delivered second-quarter results which CEO Murray Kessler described as “truly remarkable” as it lined up its oral contraceptive Opill (0.075-mg norgestrel) for OTC designation.
Age-Restriction Labeling, Behind-The-Counter Sales Likely In HRA's US OTC Contraceptive NDA
“I think the issue is whether it is going to have age restricted labeling, which would be a political issue rather than a medical issue,” says